文献速递泌尿男性生殖肿瘤

Decipher基因组分类器在根治性前列腺切除术后接受挽救性放疗且未联合激素治疗患者中的验证——SAKK 09/10随机临床试验的辅助研究

Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy - an ancillary study of the SAKK 09/10 randomized clinical trial.
PubMed 文献 · Ann Oncol · 2022-05-28

本研究在SAKK 09/10 III期随机试验中验证Decipher基因组分类器(GC)对根治性前列腺切除术后生化复发、接受挽救性放疗(64 Gy vs 70 Gy,无同期激素治疗或盆腔淋巴结放疗)患者的预后价值。226例可分析患者中,GC高危与生化进展、临床进展和激素治疗使用独立相关。GC高危患者5年无生化进展率为45%,GC低-中危为71%。

要点

  • GC高危 vs 低-中危:生化进展sHR 2.26(95%CI 1.42-3.60,P<0.001)。
  • GC高危 vs 低-中危:临床进展HR 2.29(95%CI 1.32-3.98,P=0.003)。
  • GC高危 vs 低-中危:激素治疗使用sHR 2.99(95%CI 1.55-5.76,P=0.001)。

核心结论

  • 本研究是首个在早期挽救性放疗且无同期激素治疗或盆腔淋巴结放疗患者中验证GC预后价值的当代随机对照试验。
  • 独立于标准临床病理变量和放疗剂量,GC高危患者发生生化进展、临床进展和接受挽救性激素治疗的可能性是GC较低患者的2倍以上。
  • 这些数据证实Decipher GC在术后挽救治疗场景中用于个体化同期系统治疗决策的临床价值。

研究设计与样本

  • SAKK 09/10是一项III期随机试验,350例根治性前列腺切除术后生化复发男性随机接受64 Gy vs 70 Gy挽救性放疗,无同期激素治疗或盆腔淋巴结放疗。
  • 对入组患者的根治性前列腺切除标本进行临床级全转录组检测。
  • 预设统计方案评估GC对临床结局的影响,主要终点为生化进展,次要终点为临床进展和至激素治疗时间。
  • 多变量分析校正年龄、T分期、Gleason评分、根治性前列腺切除术后持续前列腺特异性抗原(PSA)、随机化时PSA和随机化分组,并考虑竞争风险。
  • 可分析队列226例,代表整体试验人群,中位随访6.3年(四分位距6.1-7.2年)。

主要发现

  • GC高危 vs 低-中危与生化进展独立相关(sHR 2.26,95%CI 1.42-3.60;P<0.001)。
  • GC高危 vs 低-中危与临床进展独立相关(HR 2.29,95%CI 1.32-3.98;P=0.003)。
  • GC高危 vs 低-中危与激素治疗使用独立相关(sHR 2.99,95%CI 1.55-5.76;P=0.001)。
  • GC高危患者5年无生化进展率为45%,GC低-中危患者为71%。
  • 剂量递增对整体队列无获益,对GC评分较低 vs 较高的患者也无获益。

临床怎么用

  • 作者认为这些数据证实Decipher GC的临床价值,可用于术后挽救治疗场景中个体化同期系统治疗的使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Decipher genomic classifier (GC) has shown to independently prognosticate outcomes in prostate cancer. The objective of this study was to validate the GC in a randomized phase III trial of dose-escalated salvage radiotherapy (SRT) after radical prostatectomy. PATIENTS AND METHODS: A clinical-grade whole-transcriptome assay was carried out on radical prostatectomy samples obtained from patients enrolled in Swiss Group for Clinical Cancer Research (SAKK) 09/10, a phase III trial of 350 men with biochemical recurrence after radical prostatectomy randomized to 64 Gy versus 70 Gy without concurrent hormonal therapy or pelvic nodal RT. A prespecified statistical plan was developed to assess the impact of the GC on clinical outcomes. The primary endpoint was biochemical progression; secondary endpoints were clinical progression and time to hormone therapy. Multivariable analyses adjusted for age, T-category, Gleason score, postradical prostatectomy persistent prostate-specific antigen (PSA), PSA at randomization, and randomization arm were conducted, accounting for competing risks. RESULTS: The analytic cohort of 226 patients was representative of the overall trial, with a median follow-up of 6.3 years (interquartile range 6.1-7.2 years). The GC (high versus low-intermediate) was independently associated with biochemical progression [subdistribution hazard ratio (sHR) 2.26, 95% confidence interval (CI) 1.42-3.60; P < 0.001], clinical progression (HR 2.29, 95% CI 1.32-3.98; P = 0.003), and use of hormone therapy (sHR 2.99, 95% CI 1.55-5.76; P = 0.001). GC high patients had a 5-year freedom from biochemical progression of 45% versus 71% for GC low-intermediate. Dose escalation did not benefit the overall cohort, nor patients with lower versus higher GC scores. CONCLUSIONS: This study represents the first contemporary randomized controlled trial in patients treated with early SRT without concurrent hormone therapy or pelvic nodal RT that has validated the prognostic utility of the GC. Independent of standard clinicopathologic variables and RT dose, high-GC patients were more than twice as likely than lower-GC patients to experience biochemical and clinical progression and receive of salvage hormone therapy. These data confirm the clinical value of Decipher GC to personalize the use of concurrent systemic therapy in the postoperative salvage setting.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Dal Pra A, Ghadjar P, Hayoz S, et al. Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy - an ancillary study of the SAKK 09/10 randomized clinical trial. Ann Oncol. 2022. PMID: 35636621. doi:10.1016/j.annonc.2022.05.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。